CDKN2A and cancer: Patients with discordant HPV and p16 status presented an intermediate survival, with 36.5% 10-year OS and 74.1% DFS in those with HPVDNA−/p16+ TSCC/BOTSCC, while corresponding figures for those with HPVDNA+/p16− cancers were 42.9% and 80.9% for OS and DFS, respectively.